Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance
Antipsychotic-induced metabolic disturbance (AIMD) is a common adverse effect of antipsychotics with genetics partly underpinning variation in susceptibility among schizophrenia patients. Melanocortin4 receptor (MC4R) gene, one of the candidate genes for AIMD, has been under-studied in the Chinese patients. We conducted a pharmacogenetic study in a large cohort of Chinese patients with schizophrenia. In this study, we investigated the genetic variation of MC4R in Chinese population by genotyping two SNPs (rs489693 and rs17782313) in 1,991 Chinese patients and examined association of these variants with the metabolic effects that were often observed to be related to AIMD. Metabolic measures, including body mass index (BMI), waist circumference (WC), glucose, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels were assessed at baseline and after 6-week antipsychotic treatment. We found that interaction of SNP×medication status (drug-naïve/medicated) was significantly associated with BMI, WC, and HDL change %, respectively. Both SNPs were significantly associated with baseline BMI and WC in the medicated group. Moderate association of rs489693 with WC, Triglyceride, and HDL change % were observed in the whole sample. In the drug-naïve group, we found recessive effects of rs489693 on BMI gain more than 7%, WC and Triglyceride change %, with AA incurring more metabolic adverse effects. In conclusion, the association between rs489693 and the metabolic measures is ubiquitous but moderate. Rs17782313 is less involved in AIMD. Two SNPs confer risk of AIMD to patients treated with different antipsychotics in a similar way.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Science China. Life sciences - 62(2019), 4 vom: 30. Apr., Seite 535-543 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antipsychotic Agents |
|---|
| Anmerkungen: |
Date Completed 05.03.2020 Date Revised 05.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11427-018-9489-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295512784 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295512784 | ||
| 003 | DE-627 | ||
| 005 | 20231225083827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11427-018-9489-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0985.xml |
| 035 | |a (DE-627)NLM295512784 | ||
| 035 | |a (NLM)30929193 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2020 | ||
| 500 | |a Date Revised 05.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antipsychotic-induced metabolic disturbance (AIMD) is a common adverse effect of antipsychotics with genetics partly underpinning variation in susceptibility among schizophrenia patients. Melanocortin4 receptor (MC4R) gene, one of the candidate genes for AIMD, has been under-studied in the Chinese patients. We conducted a pharmacogenetic study in a large cohort of Chinese patients with schizophrenia. In this study, we investigated the genetic variation of MC4R in Chinese population by genotyping two SNPs (rs489693 and rs17782313) in 1,991 Chinese patients and examined association of these variants with the metabolic effects that were often observed to be related to AIMD. Metabolic measures, including body mass index (BMI), waist circumference (WC), glucose, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels were assessed at baseline and after 6-week antipsychotic treatment. We found that interaction of SNP×medication status (drug-naïve/medicated) was significantly associated with BMI, WC, and HDL change %, respectively. Both SNPs were significantly associated with baseline BMI and WC in the medicated group. Moderate association of rs489693 with WC, Triglyceride, and HDL change % were observed in the whole sample. In the drug-naïve group, we found recessive effects of rs489693 on BMI gain more than 7%, WC and Triglyceride change %, with AA incurring more metabolic adverse effects. In conclusion, the association between rs489693 and the metabolic measures is ubiquitous but moderate. Rs17782313 is less involved in AIMD. Two SNPs confer risk of AIMD to patients treated with different antipsychotics in a similar way | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MC4R | |
| 650 | 4 | |a antipsychotics | |
| 650 | 4 | |a metabolic disturbance | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Lipoproteins, HDL |2 NLM | |
| 650 | 7 | |a MC4R protein, human |2 NLM | |
| 650 | 7 | |a Receptor, Melanocortin, Type 4 |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 700 | 1 | |a Ren, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yue, Weihua |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Liwen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guigang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Tianlan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lifang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fuquan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianli |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Keqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Luxian |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Qingrong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fude |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lingjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chuanyue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Liansheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huiyao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaojing |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Wanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xun |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Antipsychotics Pharmacogenomics Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science China. Life sciences |d 2010 |g 62(2019), 4 vom: 30. Apr., Seite 535-543 |w (DE-627)NLM19928024X |x 1869-1889 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2019 |g number:4 |g day:30 |g month:04 |g pages:535-543 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11427-018-9489-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2019 |e 4 |b 30 |c 04 |h 535-543 | ||